DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sales of Xenpozyme® (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency [Ya...
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
– Long-term asset further increases portfolio duration – TORONTO July 2, 2024 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the "Trust"), a global leader in providing financing to advance innovation in the life sciences industry, has acquired a second royalty interest in the worldwide net sales of Xenpozyme (olipudase alfa) from HLS Therapeutics Inc. ("HLS") for an aggregate purchase price of up to US$45.75 million , comprised of a US$13.25 million upfront payment and up to US$32.5 million in performance-based outbound milestone payments. Xenpozyme is the only product developed and approved for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency ("ASMD"), also known as Niemann-Pick disease, in pediatric and adult patients. Xenpozyme was approved in Japan in March 2022 , by the European Commission in June 2022 , and by the U.S. Food and Drug Administration in August 2022 . There are no other products currently known to be in la
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Bain, Cinven Weighing Joint Bid for $20 Billion Sanofi Unit [BNN Bloomberg (Canada)]BNN Bloomberg
- Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD [Yahoo! Finance]Yahoo! Finance
- GSK to Buy CureVac's Covid-19, Flu Vaccine Rights for Up to $1.56 Billion [Yahoo! Finance]Yahoo! Finance
- Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data [Yahoo! Finance]Yahoo! Finance
- Liposomal Doxorubicin Market is Expected to Reach US$ 2,367.5 Million by 2034, Rising at a 6.3% CAGR | Future Market Insights Inc. [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 7/2/24 - Form 6-K
- 6/28/24 - Form 11-K
- 6/28/24 - Form 11-K
- SNY's page on the SEC website